YAYoshimi Asano

Yoshimi Asano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshimi Asano has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Application of N-NOSE for Evaluating the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

    by Yoshihisa Tokumaru, Yoshimi Niwa, Ryutaro Mori, Mai Okawa, Akira Nakakami, Yuta Sato, Hideyuki Hatakeyama, Takaaki Hirotsu, Eric di Luccio, Nobuhisa Matsuhashi, et al.

    Background: Breast cancer remains a leading cause of cancer-related deaths despite advances in its diagnosis and treatment. Accurate evaluation of the response to neoadjuvant chemotherapy (NAC), especially in HER2-positive and triple-negative subtypes, is critical. The current methods, including imaging and liquid biopsies, have limitations. N-NOSE, a novel urine-based cancer screening test using Caenorhabditis elegans (C. elegans) chemotaxis, offers a non-invasive alternative. This study investigates the potential of N-NOSE to predict the NAC response in breast cancer patients for improved treatment evaluations. Materials and Methods: This prospective study enrolled 36 breast cancer patients undergoing NAC and surgery to assess the predictive power of the N-NOSE method using urine samples. A chemotaxis analysis of C. elegans was used to calculate the index reduction scores (IRS1–3), reflecting the changes in tumor-related odorants across the treatment stages. Results: Between August 2020 and May 2023, 36 breast cancer patients were enrolled to evaluate the predictive value of N-NOSE IRSs for NAC response. A pathological complete response (pCR) was achieved in 36.1% of the patients. Among the three IRS types analyzed in the 35 patients, IRS3, which showed the IRS at pre-treatment minus that after surgery, showed the highest predictive performance for a pCR, with an AUC of 0.75, indicating its potential utility as a non-invasive biomarker for treatment response evaluations. Conclusions: Index reduction scores evaluated using the N-NOSE method may reflect the efficacy of NAC in breast cancer patients. Future large-scale and multi-institutional prospective studies are warranted.


  • Open Access

    The mode of progressive disease affects the prognosis of patients with metastatic breast cancer

    by Ryutaro Mori, Manabu Futamura, Kasumi Morimitsu, Yoshimi Asano, Yoshihisa Tokumaru, Mai Kitazawa, Kazuhiro Yoshida

    According to the Response Evaluation Criteria in Solid Tumors (RECIST), progressive disease (PD) is diagnosed under two conditions: an increase in size of pre-existing lesions (IS) and the appearance of new lesions (NL). We retrospectively investigated the difference in the prognosis between IS and NL. Patients receiving drug therapies for metastatic breast cancer between 2004 and 2015 at our institution were reviewed. The survival time after NL and IS was compared and the frequency of NL with each drug calculated. For the 107 eligible patients, the survival time after NL at second-line chemotherapy was significantly worse than after IS (median survival time 4.3 months vs. 20.3 months, p = 0.0048). Maintenance therapy with bevacizumab or trastuzumab had a high frequency of NL (88.9%), and third-line eribulin had a low frequency of NL (16.7%). A multivariate analysis showed that NL at second-line chemotherapy was not an independent risk factor (hazard ratio 1.02, 95%; confidence interval 0.54–1.93, p = 0.95) for the total survival time. Patients with IS had a better survival after PD than those with NL. We may be able to avoid changing drug therapy for patients without NL and allow them to continue drug therapy for longer.


  • Open Access

    A case of carcinoma of the papilla of Vater in a young man after subtotal colectomy for familial adenomatous polyposis

    by Shuji Komori, Masahiko Kawai, Toyoo Nitta, Yusuke Murase, Keita Matsumoto, Chika Shinoda, Masashi Kuno, Yuki Sasaguri, Masahiro Fukada, Yoshimi Asano, et al.

    Carcinoma and adenoma of the duodenum, including the papilla of Vater, are problematic diseases in patients with familial adenomatous polyposis (FAP). A 36-year-old man underwent a periodic medical examination for early colon cancer originating from FAP for which laparoscopic-assisted subtotal colectomy with a J-shaped ileal pouch-rectal anastomosis was performed 3 years earlier. A tumor was detected at the papilla of Vater along with elevation of total bilirubin and hepatobiliary enzymes. Although cytology did not determine the tumor to be an adenocarcinoma, we suspected adenocarcinoma due to its hypervascularity shown by contrast-enhanced computed tomography. Pylorus-preserving pancreaticoduodenectomy with modified Imanaga reconstruction and regional lymph node dissection (D2) was performed. The pathological study showed that the tumor was a papillary and moderately differentiated tubular adenocarcinoma. The patient is currently in good health without recurrence, weight loss, or severe diarrhea at 12 months after surgery. Awareness of biliary-pancreatic symptoms and periodic gastroduodenoscopy might contribute both to the early detection of duodenal or periampullary polyps and cancer and to the radical treatment of FAP. Modified Imanaga reconstruction has the potential to become one of the more effective procedures for providing good quality of life to FAP patients with duodenal or periampullary cancer.